9.1 Prospective Drug Utilization Review & Patient Profiles
Key Takeaways
- Under OBRA '90 and Kentucky regulation (201 KAR 2:210), a pharmacist must conduct a prospective Drug Utilization Review (DUR) prior to dispensing every new and refill prescription.
- Prospective DUR mandates screening across six clinical categories: 1) Therapeutic duplication, 2) Drug-disease contraindications, 3) Drug-drug interactions (including OTCs), 4) Incorrect dosage or duration, 5) Drug-allergy interactions, and 6) Clinical abuse or misuse.
- Pharmacies must make a reasonable effort to create and maintain comprehensive patient profiles containing demographic, clinical, allergy, and complete medication/device histories.
- Patient profile records, dispensing logs, and clinical DUR interventions must be retained for a minimum of five (5) years under Kentucky law (201 KAR 2:171).
- Automated computer system alerts do not satisfy the DUR requirement; the pharmacist must independently exercise professional judgment and document clinical resolutions.
9.1 Prospective Drug Utilization Review & Patient Profiles
Patient safety and optimal therapeutic outcomes depend on proactive clinical surveillance at the point of dispensing. In pharmacy jurisprudence, this legal and clinical duty is operationalized through Prospective Drug Utilization Review (DUR) and Comprehensive Patient Profile Maintenance. Originally codified at the federal level under the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) for Medicaid beneficiaries, the Commonwealth of Kentucky expanded these clinical mandates through 201 KAR 2:210 to protect all patients receiving prescription medications from any licensed pharmacy.
1. Legal Foundations: OBRA '90 & Kentucky Expansion
To understand the legal structure governing modern pharmacy practice, candidates must distinguish between federal statutory origins and Kentucky's universal administrative implementation:
┌─────────────────────────────────────────────────────────────────────────────┐
│ DUR LEGAL EVOLUTION & JURISDICTION │
├─────────────────────────────────────────────────────────────────────────────┤
│ FEDERAL BASELINE: OBRA '90 (42 U.S.C. § 1396r-8) │
│ • Condition of state participation in Medicaid reimbursement. │
│ • Mandated prospective DUR, patient profiling, and counseling offers for │
│ outpatient Medicaid recipients only. │
│ │
│ KENTUCKY EXPANSION: 201 KAR 2:210 (Kentucky Board of Pharmacy) │
│ • Expanded OBRA '90 standards to ALL patients receiving prescriptions. │
│ • Applies across all practice settings dispensing outpatient prescriptions │
│ (community, retail, mail-order, outpatient clinic, charitable). │
│ • Applies regardless of payor (commercial insurance, Medicare, Medicaid, │
│ cash/uninsured, worker's compensation). │
└─────────────────────────────────────────────────────────────────────────────┘
The Three Tiers of Drug Utilization Review
Drug Utilization Review operates across three distinct temporal phases within the healthcare delivery continuum:
- Prospective DUR: Evaluation of the drug therapy before the prescription is dispensed or administered to the patient. Performed at the pharmacy level by the dispensing pharmacist.
- Concurrent DUR: Real-time monitoring of drug therapy during the course of treatment (e.g., inpatient clinical monitoring of therapeutic drug levels, organ function adjustments, anticoagulant tracking).
- Retrospective DUR: Post-dispensing review of historical claims data conducted by state Medicaid committees or Pharmacy and Therapeutics (P&T) committees over weeks or months to identify patterns of fraud, over-prescribing, therapeutic duplication, or systemic non-adherence.
2. The Six Mandatory Elements of Prospective DUR
Under 201 KAR 2:210, Section 2, prior to dispensing any new prescription or refill, the pharmacist shall examine the patient record and each prescription presented for dispensing to identify potential clinical problems across six core categories:
| DUR Screening Category | Clinical Definition & Scope | High-Yield Practice Scenario |
|---|---|---|
| 1. Therapeutic Duplication | Concurrent prescribing of two or more medications from the same pharmacological class or with identical therapeutic mechanisms without clinical justification. | Patient presents a prescription for escitalopram from a psychiatrist while currently receiving sertraline from a primary care provider. |
| 2. Drug-Disease Contraindications | Prescribing a medication that is clinically contraindicated or likely to exacerbate an existing pathological condition or disease state. | Prescribing non-selective beta-blockers (e.g., propranolol) to a patient with severe asthma, or systemic decongestants (pseudoephedrine) to a patient with uncontrolled malignant hypertension. |
| 3. Drug-Drug Interactions | Pharmacokinetic or pharmacodynamic interactions between concurrent medications (including serious interactions with OTC drugs) that alter efficacy or toxicity. | Co-administration of sildenafil with isosorbide mononitrate (severe life-threatening refractory hypotension), or simvastatin with clarithromycin (CYP3A4 inhibition leading to severe rhabdomyolysis). |
| 4. Incorrect Dosage or Duration | Prescribing drug quantities, single doses, daily frequencies, or treatment durations outside established clinical ranges (too high or too low). | Prescribing amoxicillin/clavulanate 875 mg BID for 60 consecutive days for acute otitis media, or dispensing adult doses of liquid medications to pediatric patients without weight-based adjustment. |
| 5. Drug-Allergy Interactions | Co-prescribing medications in a patient with a documented immunological hypersensitivity or known cross-reactivity. | Dispensing cephalexin or amoxicillin to a patient with a documented history of severe IgE-mediated anaphylactic shock to penicillin. |
| 6. Clinical Abuse or Misuse | Patterns of medication utilization indicating psychological addiction, diversion, doctor shopping, early refill requests, or severe underutilization/non-adherence. | Patient presenting overlapping Schedule II or IV prescriptions from multiple unrelated clinics, or requesting a 30-day supply refill on day 12 of a 30-day opioid prescription. |
Exam Alert — Over-the-Counter (OTC) Interaction Screening: Note that DUR screening category 3 explicitly encompasses serious drug-drug interactions involving over-the-counter products. Pharmacists cannot ignore known OTC usage documented in the patient profile when evaluating prescription safety (e.g., chronic OTC high-dose ibuprofen interacting with prescribed lisinopril or warfarin).
3. Patient Profile Maintenance Mandates (201 KAR 2:210)
To enable an effective prospective DUR, every pharmacy must make a reasonable effort to obtain, record, and maintain an accurate, updated patient profile for every individual receiving pharmaceutical care.
Mandatory Profile Data Elements
Under Kentucky law (201 KAR 2:210, Section 1), the patient record system must contain, at a minimum, the following information:
┌─────────────────────────────────────────────────────────────────────────────┐
│ MANDATORY PATIENT PROFILE ELEMENTS │
├─────────────────────────────────────────────────────────────────────────────┤
│ 1. Demographics: │
│ • Full legal name of the patient │
│ • Residential address and telephone number │
│ • Date of birth (or age) and gender │
│ │
│ 2. Clinical & Medical History: │
│ • Known disease states, chronic conditions, and physical impairments │
│ • Known drug allergies, idiosyncratic reactions, or drug sensitivities │
│ (Must record 'No Known Drug Allergies / NKDA' if none reported) │
│ │
│ 3. Medication & Device History: │
│ • Comprehensive list of all prescription medications dispensed │
│ • Relevant over-the-counter (OTC) medications and herbal supplements │
│ • List of medical devices utilized (e.g., spacers, testing meters) │
│ │
│ 4. Pharmacist Clinical Notes: │
│ • Relevant comments regarding the individual's drug therapy │
│ • Documentation of clinical interventions, alerts overridden, or │
│ communication with prescribers │
└─────────────────────────────────────────────────────────────────────────────┘
The "Reasonable Effort" Standard & Patient Refusal
- Pharmacy personnel must actively request profile information from the patient or their authorized caregiver upon enrollment and when new prescriptions are presented.
- Patient Right to Withhold Information: A patient has the legal right to decline to provide demographic, disease, or allergy history. If a patient refuses or fails to provide the information, the pharmacy may still dispense the medication, provided that the pharmacist or staff documents the refusal or inability to obtain the information in the patient's record.
- A pharmacy cannot arbitrarily refuse to serve a patient solely because the patient declines to disclose optional historical health details, provided the pharmacist can ensure the safety of the specific dispensing event.
4. Record Retention: The Kentucky 5-Year Mandate
A critical high-yield topic on the Kentucky MPJE is the retention period for pharmacy records:
| Record Type | Federal Statutory Baseline | Kentucky Law (Prevailing Standard) | Governing Regulation |
|---|---|---|---|
| Patient Medication Profiles | Not specified in FDCA (2 yrs for Medicare Part D) | Five (5) Years from the date of the last entry | 201 KAR 2:171 / 201 KAR 2:210 |
| Prescription Records (C-II to C-V & Non-Controlled) | 2 Years under DEA (21 CFR § 1304.04) | Five (5) Years from the date of dispensing | KRS 315.191 / 201 KAR 2:171 |
| DUR Clinical Intervention Logs | Not specified federally | Five (5) Years | 201 KAR 2:210 |
| Patient Counseling Refusal Documentation | Not specified federally | Five (5) Years | 201 KAR 2:210 |
| HIPAA Privacy & NPP Acknowledgments | Six (6) Years under HIPAA | Six (6) Years (Federal Stricter Rule) | 45 CFR § 164.530(j) |
Exam Trap — 2 Years vs. 5 Years vs. 6 Years: Examinees frequently confuse federal DEA recordkeeping (2 years) with Kentucky pharmacy law. In Kentucky, all prescription files, patient profiles, and dispensing logs must be retained for five (5) years. However, HIPAA privacy acknowledgments and policies require six (6) years under federal law. Always apply the stricter prevailing standard!
5. Automated System Overrides & Pharmacist Accountability
Modern pharmacy dispensing software utilizes automated clinical decision support (CDS) algorithms that generate color-coded alerts for drug interactions, dosing bounds, and duplicate therapies. On the MPJE, remember these vital principles:
- Alert Fatigue Does Not Eliminate Liability: The existence of automated warning algorithms does not discharge the pharmacist's legal responsibility. If a computer system flags a fatal interaction and the pharmacist bypasses the prompt without clinical evaluation, the pharmacist is personally liable for unprofessional conduct under KRS 315.121.
- Mandatory Documentation of Critical Overrides: When a pharmacist overrides a high-severity prospective DUR alert (e.g., major QT prolongation, drug-allergy flag), the pharmacist must document the clinical rationale (e.g., "Prescriber contacted, verified baseline ECG normal, patient educated on symptoms") in the pharmacy system.
- Delegation Prohibited: Only a licensed pharmacist or a registered pharmacy intern under immediate supervision can perform the DUR and authorize an alert override. Pharmacy technicians, clerks, and cashiers are strictly prohibited from evaluating or overriding clinical DUR alerts.
A community pharmacist in Bowling Green is reviewing an electronic prescription for clarithromycin 500 mg BID for a 62-year-old patient. The pharmacy's computerized profile indicates the patient is actively taking simvastatin 40 mg daily (a major CYP3A4 substrate with high risk of rhabdomyolysis when combined with macrolides). Under 201 KAR 2:210, which of the following actions is legally and professionally required of the pharmacist?
Under Kentucky Administrative Regulations (201 KAR 2:171 and 201 KAR 2:210), what is the minimum statutory retention period for patient medication profiles and documented clinical DUR interventions?
A new patient visits a retail pharmacy in Louisville to drop off an initial prescription for lisinopril. When the technician asks the patient for their date of birth, home address, known medical conditions, and drug allergies, the patient refuses to answer any medical questions, stating it violates their privacy. How should the pharmacy handle this scenario under 201 KAR 2:210?